Uppsala, May 5, 2023. Senzime AB (publ) (”Senzime”) hereby announces that the nomination committee adjusts the previous proposals regarding the number of members of the board of directors and election of members of the board of directors and chairman of the board of directors at the annual general meeting 2023.

Senzime announced by a press release on May 3, 2023, that the company’s board of directors had decided to appoint Philip Siberg as the new CEO and that Adam Dahlberg succeeds Philip Siberg as chairman of the board.

By reason of the above, the nomination committee, consisting of Adam Dahlberg (chair), Gabriel Urwitz, Malin Björkmo and Philip Siberg, has resolved to adjust its proposals for resolutions with respect to items 8 and 10 on the agenda for the annual general meeting 2023. All other proposals from the nomination committee remain unchanged. The adjusted proposals for the items 8 and 10 on the agenda are as follows:

Item 8 – Resolution on the number of members of the board of directors and number of deputy members of the board of directors

The nomination committee proposes that the board of directors shall consist of six (6) directors without any deputy directors.

Item 10 – Election of members of the board of directors, chairman of the board of directors and deputy members of the board of directors

The nomination committee proposes re-election of Adam Dahlberg, Sorin Brull, Eva Walde, Jenny Freeman and Laura Piccinini and election of Göran Brorsson as members of the board of directors. Lennart Kalén has informed the nomination committee that he is not available for re-election. It is proposed that Adam Dahlberg is elected as chairman of the board of directors.

Göran Brorsson has over 40 years of experience from services in sales, marketing, and finance as well as leading roles at various companies. Between the years 2000 and 2015, Göran Brorsson was CEO of Elos Medtech AB. Since 2015, Göran has mainly been active as a consultant in the Medtech area. Göran Brorsson has a master’s degree in business administration from Gothenburg University.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Paula Treutiger, Head of Communication and IR
Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Senzime’s nomination committee adjusts its proposal for resolutions at the annual general meeting

© Modular Finance, source Nordic Press Releases